Acute Respiratory Infection clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18-80
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Los Angeles, California and other locations